# Royalty Pharma

> Royalty Pharma buys biopharmaceutical royalty interests and funds drug development and commercialization in exchange for future payments. Its partners include biotechnology companies, global drugmakers, universities and nonprofits; public investors access the portfolio through Nasdaq-listed RPRX.

- **Founded:** 1996
- **Headquarters:** New York, United States
- **Founders:** Pablo Legorreta (Founder, Chief Executive Officer and Chairman)
- **Products:** Existing royalty acquisitions, Synthetic royalty financing, Development and launch funding, M&A financing support
- **Notable:** Founded in 1996 and began Nasdaq trading as RPRX in June 2020., Completed the $3.3 billion cystic fibrosis royalty acquisition in 2014., Reported $3.254 billion in 2025 Portfolio Receipts and $2.6 billion in capital deployed.

## Products & services

- **Existing royalty acquisitions** — Lump-sum purchases of existing royalty rights from companies, academic institutions, inventors and nonprofits.
- **Synthetic royalty financing** — Capital in exchange for newly created contractual royalties on a partner’s future product sales.
- **Development and launch funding** — Funding for clinical development or commercialization, with returns linked to specified therapies.
- **M&A financing support** — Royalty-based capital to help partners finance acquisitions.

## Achievements

- Founded in 1996 and began Nasdaq trading as RPRX in June 2020.
- Completed the $3.3 billion cystic fibrosis royalty acquisition in 2014.
- Reported $3.254 billion in 2025 Portfolio Receipts and $2.6 billion in capital deployed.
- Completed the acquisition of its external manager on May 16, 2025.

## Latest updates

- **2026-10** — Declared a fourth-quarter dividend of $0.235 per Class A ordinary share on October 16; third-quarter results scheduled for November 4.
- **2026-09** — Announced a $7.5 million gift to Blood Cancer United’s Therapy Acceleration Program on September 15.
- **2026-08** — Q2 Portfolio Receipts were $773 million; raised 2026 Portfolio Receipts guidance to $3.4-$3.5 billion. Guidance is a forecast.

## Links

- Website: https://www.royaltypharma.com/
- LinkedIn: https://www.linkedin.com/company/royalty-pharma/

---

Profile page: https://yespress.io/royalty-pharma
Published by YesPress — https://yespress.io
Last updated: 2026-10-22